Market overview
The global nasal spray market is worth USD 35.0 bn in 2026 and is forecast to reach USD 59.8 bn by 2036, growing at a 5.5% CAGR. United States is the largest country market and Corticosteroids is the largest by drug class segment.
| Scope | Nasal sprays for allergy, congestion, cold, steroid, saline, migraine, vaccine and hormone delivery, covering over-the-counter and prescription products. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 33.0 bn |
| Value 2026 | USD 35.0 bn |
| Value 2036 | USD 59.8 bn |
| CAGR 2026-2036 | 5.5% |
| Volume 2026 | 5,772 million units |
| Volume 2036 | 8,926 million units |
| Average price 2026 | USD 6.06 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Nasal Spray market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 35.0 bn |
| 2027 | USD 36.9 bn |
| 2028 | USD 38.9 bn |
| 2029 | USD 41.1 bn |
| 2030 | USD 43.3 bn |
| 2031 | USD 45.7 bn |
| 2032 | USD 48.2 bn |
| 2033 | USD 50.9 bn |
| 2034 | USD 53.7 bn |
| 2035 | USD 56.6 bn |
| 2036 | USD 59.8 bn |
Nasal Spray market segmentation
By drug class
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Corticosteroids | 26.0% | 24.4% | USD 9.1 bn | 4.8% |
| Decongestants | 20.0% | 15.5% | USD 7.0 bn | 2.9% |
| Saline and moisturising | 22.0% | 23.8% | USD 7.7 bn | 6.3% |
| Antihistamines | 12.0% | 11.3% | USD 4.2 bn | 4.8% |
| Other prescription sprays | 20.0% | 24.9% | USD 7.0 bn | 7.8% |
By channel
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Retail pharmacies | 52.0% | 47.8% | USD 18.2 bn | 4.6% |
| Hospital pharmacies | 12.0% | 11.6% | USD 4.2 bn | 5.1% |
| Online | 22.0% | 29.4% | USD 7.7 bn | 8.6% |
| Supermarkets and others | 14.0% | 11.2% | USD 4.9 bn | 3.1% |
By access
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Over-the-counter | 56.0% | 52.9% | USD 19.6 bn | 4.9% |
| Prescription | 36.0% | 39.2% | USD 12.6 bn | 6.4% |
| Behind-the-counter and others | 8.0% | 7.9% | USD 2.8 bn | 5.4% |
By spray format
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Metered-dose pump sprays | 62.0% | 58.0% | USD 21.7 bn | 4.8% |
| Pressurized aerosol sprays | 18.0% | 16.0% | USD 6.3 bn | 4.3% |
| Unit-dose and powder sprays | 20.0% | 26.0% | USD 7.0 bn | 8.3% |
By patient age
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Adults | 62.0% | 60.0% | USD 21.7 bn | 5.2% |
| Adolescents | 18.0% | 18.0% | USD 6.3 bn | 5.5% |
| Children and infants | 20.0% | 22.0% | USD 7.0 bn | 6.5% |
Top 25 countries for nasal spray by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 81.0% of 2026 revenue and the 25 countries below together hold 95.0%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 12.6 bn | 36.0% | USD 21.5 bn | 5.5% |
| 2 | China | USD 3.5 bn | 10.0% | USD 6.9 bn | 7.0% |
| 3 | Japan | USD 2.4 bn | 7.0% | USD 3.6 bn | 4.1% |
| 4 | Germany | USD 2.1 bn | 6.0% | USD 3.1 bn | 4.0% |
| 5 | France | USD 1.7 bn | 5.0% | USD 2.6 bn | 3.9% |
| 6 | United Kingdom | USD 1.4 bn | 4.0% | USD 2.2 bn | 4.4% |
| 7 | India | USD 1.4 bn | 4.0% | USD 3.3 bn | 8.9% |
| 8 | Italy | USD 1.0 bn | 3.0% | USD 1.6 bn | 4.0% |
| 9 | Brazil | USD 1.0 bn | 3.0% | USD 1.9 bn | 5.8% |
| 10 | Canada | USD 1.0 bn | 3.0% | USD 1.7 bn | 5.1% |
| 11 | Spain | USD 791 mn | 2.3% | USD 1.4 bn | 5.5% |
| 12 | Mexico | USD 700 mn | 2.0% | USD 1.2 bn | 5.5% |
| 13 | Australia | USD 570 mn | 1.6% | USD 974 mn | 5.5% |
| 14 | South Korea | USD 504 mn | 1.4% | USD 860 mn | 5.5% |
| 15 | Netherlands | USD 444 mn | 1.3% | USD 759 mn | 5.5% |
| 16 | Russia | USD 378 mn | 1.1% | USD 645 mn | 5.5% |
| 17 | Turkey | USD 322 mn | 0.9% | USD 550 mn | 5.5% |
| 18 | Poland | USD 255 mn | 0.7% | USD 436 mn | 5.5% |
| 19 | Sweden | USD 206 mn | 0.6% | USD 353 mn | 5.5% |
| 20 | Switzerland | USD 175 mn | 0.5% | USD 299 mn | 5.5% |
| 21 | Belgium | USD 150 mn | 0.4% | USD 257 mn | 5.5% |
| 22 | Argentina | USD 126 mn | 0.4% | USD 215 mn | 5.5% |
| 23 | Saudi Arabia | USD 112 mn | 0.3% | USD 191 mn | 5.5% |
| 24 | Indonesia | USD 98 mn | 0.3% | USD 167 mn | 5.5% |
| 25 | Taiwan | USD 80 mn | 0.2% | USD 137 mn | 5.5% |
| Rest of world | USD 1.7 bn | 5.0% | USD 3.1 bn | 5.9% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Haleon
- Bayer
- Sanofi
- Kenvue
- Viatris
- Teva Pharmaceutical
- Organon
- Procter and Gamble
Group 2: Regional and specialist players
- Perrigo
- Sun Pharmaceutical
- Cipla
- Glenmark
- Dr. Reddy's Laboratories
- Lupin
- Zydus Lifesciences
- Apotex
- Church and Dwight
Group 3: Emerging and niche players
- Neurelis
- ARS Pharmaceuticals
- SinoFresh Healthcare
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the nasal spray market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.5% is calculated from the resulting values.
The market is divided by drug class, by channel, by access, by spray format, by patient age. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the nasal spray market?
The global nasal spray market is estimated at USD 33.0 bn in 2025 and USD 35.0 bn in 2026.
How fast will the nasal spray market grow?
It is forecast to reach USD 59.8 bn by 2036, a compound annual growth rate of 5.5% from 2026, an increase of USD 24.8 bn.
Which country is the largest market for nasal spray?
United States is the largest market by revenue at USD 12.6 bn in 2026, 36.0% of the global total. The three largest countries together hold 53.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 8.9% a year from 2026 to 2036.
Which nasal spray segment is largest?
In the by drug class split, Corticosteroids is the largest segment with 26.0% of 2026 revenue.
Who are the leading nasal spray companies?
Global leaders include Haleon, Bayer, Sanofi, Kenvue.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Clinical NutritionUSD 35.3 bn · 7.0% CAGR
- Obesity DrugsUSD 33.3 bn · 14.0% CAGR
- Diabetes CareUSD 32.7 bn · 9.0% CAGR
- BiosimilarsUSD 37.8 bn · 15.0% CAGR
- Molecular DiagnosticsUSD 32.4 bn · 8.0% CAGR
- Regenerative MedicineUSD 31.6 bn · 13.0% CAGR
- Inhalation Drug DeliveryUSD 40.1 bn · 5.5% CAGR
- Medical TourismUSD 40.3 bn · 12.0% CAGR